Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series
Live moderated video webcast on Wednesday, July 12th at 10:00 AM ET
FRAMINGHAM, MA / ACCESSWIRE / July 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced that Jeffrey Eisenberg, Chief Executive Officer and Curtis A. Lockshin, PhD, Chief Scientific Officer of Xenetic Biosciences will participate in the Virtual Investor Summer Spotlight Series on Wednesday, July 12, 2023 at 10:00 AM ET.
A live video webcast of the presentation will be available on the Events page in the Investors section of the Company's website (www.XeneticBio.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
JTC Team, LLC
SOURCE: Xenetic Biosciences, Inc.
View source version on accesswire.com:
Released July 5, 2023